Alkem Laboratories appoints Rajpal Singh Rana as SVP - Marketing & Sales
Alkem Laboratories Limited appointed Rajpal Singh Rana as Senior Vice President - Marketing & Sales for the Acute Cluster on August 3, 2026. Rana brings over 30 years of industry experience and holds an MBA from Sikkim Manipal University. The appointment was disclosed under Regulation 30 of the SEBI LODR Regulations.

*this image is generated using AI for illustrative purposes only.
Alkem Laboratories Limited has appointed Rajpal Singh Rana as Senior Vice President - Marketing & Sales for the Acute Cluster, effective August 3, 2026. The company disclosed the senior management change to the stock exchanges pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. This leadership addition aims to strengthen the company’s commercial operations in its acute care segment.
The appointment was communicated to the Bombay Stock Exchange and the National Stock Exchange of India Limited on August 3, 2026. Divya Mewani, Vice President – Legal & Deputy Company Secretary at Alkem Laboratories, signed the disclosure letter. The company stated that the information is also available on its official website.
Appointment Details
Rana’s contract term is defined as continuing for as long as he remains in the employment of the company. The filing did not disclose any specific fixed tenure or performance-linked exit clauses. There are no disclosed relationships between Rana and the company’s directors.
| Particulars | Details |
|---|---|
| Name | Rajpal Singh Rana |
| Designation | Senior Vice President - Marketing & Sales |
| Effective Date | August 3, 2026 |
| Term | Duration of employment |
Professional Profile
Rana is an experienced pharmaceutical professional with over 30 years of experience in marketing and sales. Before joining Alkem Laboratories, he worked with various other pharmaceutical companies. He holds an MBA in Marketing from Sikkim Manipal University and a B.Sc. in Physics, Chemistry & Mathematics from Delhi University.
Regulatory Context
The disclosure was made under Regulation 30(2) of the SEBI LODR Regulations, read with Schedule III, Part A. The company also referenced the SEBI Master Circular bearing number HO/49/14/14(7)2025-CFDPOD2/1/3762/2026 dated January 30, 2026, regarding the format and content of such disclosures. The appointment does not involve any change in the board composition or promoter holding.
Historical Stock Returns for Alkem Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.77% | +1.30% | +2.46% | +2.55% | +13.43% | +63.88% |
How is Alkem Laboratories planning to leverage Rajpal Singh Rana's 30 years of experience to differentiate its acute care products in a competitive market?
What specific revenue growth targets or market share expansions has Alkem set for the Acute Cluster under Rana's new leadership?
Will this appointment signal a broader strategic shift in Alkem's marketing approach, such as increased focus on digital sales channels or key account management?


































